Aethiopathogenesis of mastocytosis: Current options;Etiopatogeneza mastocytozy w świetle współczesnych poglacombining ogonekdów

Postepy Dermatologii i Alergologii

Volumn 26, Issue 3, 2009, Pages 142-145

  Lange, Magdalena ^a   Niedoszytko, Marek ^b   Nedoszytko, Bogusław ^a   Gleń, Jolanta ^a  

^a Klinika Dermatologiczna Medical University of Warsaw   (Poland)

^b Klinika Alergologii   (Poland)

Author keywords

Classification; Mastocytosis; Pathogenesis

Indexed keywords

CELL ADHESION MOLECULE; MEMBRANE ANTIGEN; STEM CELL FACTOR RECEPTOR;

APOPTOSIS; CELL PROLIFERATION; GENE EXPRESSION; GENE MUTATION; GENETIC DISORDER; GENETIC HETEROGENEITY; GENETIC POLYMORPHISM; HEREDITY; HUMAN; MAST CELL; MASTOCYTOSIS; PATHOGENESIS; REVIEW; SYMPTOMATOLOGY;

EID: 70449732586     PISSN: 1642395X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. Valent P, Akin C, Sperr WR, et al. Diagnosis and treatment of systemic mastocytosis: state of the art. Br J Haematol 2003; 122: 695-717. (Pubitemid 37100296)
2. Escribano L, Akin C, Castells M, et al. Mastocytosis: current concepts in diagnosis and treatment. Ann Hematol 2002; 81: 677-690 (Pubitemid 36104422)
3. Roszkiewicz J, Lange M. Mastocytozy: spektrum kliniczne, diagnostyka, leczenie. Przegl Dermatol 2000; 87: 369-377
4. Hartman K, Henz BM. Mastocytosis: recent advances in defining the disease. Br J Dermatol 2001; 144: 682-695 (Pubitemid 32374769)
5. Lange M, Szczerkowska-Dobosz A, Jasiel-Walikowska E. Mastocytoza ukcombining ogonekadowa - spektrum kliniczne, diagnostyka i leczenie. Przegl Dermatol 2005; 3: 245-250 (Pubitemid 41008318)
6. Renke J, Lange M. Mastocytoza u dzieci. Przegl Lek 2006; 63/7: 551-553
7. Horny HP, Valent P. Diagnosis of mastocytosis: general histopathological aspects, morphological criteria, and immunohistochemical findings. Leuk Res 2001; 25: 543-551 (Pubitemid 32506761)
8. Akin C, Metcalfe DD. Surrogate markers of disease in mastocytosis. Int Arch Allergy Immunol 2002; 127: 133-136
9. Metcalfe DD, Akin C. Mastocytosis: molecular mechanisms and clinical disease heterogeneity. Leuk Res 2001; 25: 577-582 (Pubitemid 32506765)
10. Valent P, Akin C, Sperr WR, al. Mastocytosis: pathology, genetics, and current options for therapy. Leuk Lymphoma 2005; 46: 35-48.
11. Valent P, Sperr WR, Schwartz LB, Horny HP. Diagnosis and classification of mast cell proliferative disorders: Delineation from immunologic diseases and non-mast cell hematopoietic neoplasmas. J Allergy Clin Immunol 2004; 114: 3-11. (Pubitemid 39005111)
12. Niedoszytko M. Epidemiologia. W: Mastocytoza: rozpoznanie i leczenie. Niedoszytko M, Jassem E, Kruszewski J (red.). Agencja Benkowski, Biacombining ogonekystok 2007; 23.
13. Kuna P, Jarmakowska K. Patofizjologia. W: Mastocytoza: rozpoznanie i leczenie. Niedoszytko M, Jassem E, Kruszewski J (eds). Agencja Benkowski, Biacombining ogonekystok 2007; 27-41.
14. Akin C. Mast cell activation disorders. ECNM 2008 Abstract book: 31.
15. Niedoszytko M. Mastocytoza - rozrostowa choroba komórek tucznych zwiacombining ogonekzana z ryzykiem reakcji anafilaktycznej. Pol Merk Lek 2006; 126: 570-572 (Pubitemid 46129194)
16. Lange M, Kaszuba A. Uogólniona skórna mastocytoza przebiegajacombining ogonekca z anafilaksjacombining ogonek. Post Dermatol Alergol 2007; 1: 52-57
17. Marciniak J, Jutel M. Znaczenie mastocytozy w reakcjach anafilaktycznych. Post Dermatol Alergol 2006; 1: 17-20.
18. Wasacombining ogonekg B. Zaburzenia genetyczne. W: Mastocytoza: rozpoznanie i leczenie. Niedoszytko M, Jassem E, Kruszewski J (red.). Agencja Benkowski, Biacombining ogonekystok 2007; 42-44
19. Garcia-Montero AC, Jara-Acevedo M, Teodosio C, et al. KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood 2006; 108: 2366-2372 (Pubitemid 44497521)
20. Peavy R, Metcalfe D. Understanding the mechanisms of anaphylaxis. Curr Opin Allergy Clin Immunol 2008; 8: 310-315
21. Vennekenens R, Olausson J, Meissner M, et al. Increased IgE dependent mast cell activation and anaphylactic responses in mice lacking the calcium activated nonselective cation channel TRPM4. Nat Immunol 2007; 8: 312-320 (Pubitemid 46745381)
22. Feger F, Dumas AR, Leriche L, et al. Kit and c-kit Mutations: a short overview with special reference to novel molecular and diagnostic concepts. Int Arch Allergy Immunol 2002; 127: 110-114 (Pubitemid 34264196)
23. Brockow K, Jofer C, Behrendt H, Ring J. Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients. Allergy 2008; 63: 226-232
24. Hirota S, Isozaki K, Hashimoto K, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998; 279: 577-580 (Pubitemid 28067289)
25. Tian Q, Frierson HF, Krystal GW, Moskaluk CA. Activating c-kit gene mutations in human germ cell tumors. Am J Path 1999; 154: 1643-1647 (Pubitemid 29262845)
26. Pardanani A, Akin C, Valent P. Pathogenesis, clinical features, and treatment advances in mastocytosis. Best Pract Res Clin Haematol 2006; 19: 595-615. (Pubitemid 43869476)
27. Hartman K, Hermes B, Rappersberger K, et al. Evidence for altered mast cell proliferation and apoptosis in cutaneous mastocytosis. Br J Dermatol 2003; 149: 554-559 (Pubitemid 37281587)
28. Caughey G. Tryptase genetics and anaphylaxis. J Allergy Clin Immunol 2006; 117: 1411-1414
29. Akin C, Soto D, Brittain E. Tryptase haplotype in mastocytosis: relationship to disease variant and diagnostic utility of total tryptase levels. Clin Immunol 2007; 123: 268-271 (Pubitemid 46818128)
30. Nedoszytko B, Niedoszytko M, Lange M, et al. Interleukin-13 promoter gene polymorphism - 1112C/T is associated with the systemic form of mastocytosis. Allergy 2009; 64: 287-294